Evidence map›Paper›PMID 38175383›Full record

ArticleJournal of gastrointestinal cancer2024

POLE-Mutant Colon Adenocarcinoma-Case Presentation and Histopathological Evaluation.

Tamás Pancsa, Béla Vasas, Zsombor Melegh, Erika Tóth, László Torday, Anita Sejben

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tamás PancsaDepartment of Pathology, University of Szeged, Állomás U. 1, Szeged, 6725, Hungary.ORCID http://orcid.org/0009-0005-1643-6233
Béla VasasDepartment of Pathology, University of Szeged, Állomás U. 1, Szeged, 6725, Hungary.ORCID http://orcid.org/0000-0001-8499-8442
Zsombor MeleghCenter of Tumor Pathology, Department of Surgical and Molecular Pathology, National Institute of Oncology Hungary, Ráth György U. 7-9, Budapest, 1122, Hungary.ORCID http://orcid.org/0000-0001-7605-5719
Erika TóthCenter of Tumor Pathology, Department of Surgical and Molecular Pathology, National Institute of Oncology Hungary, Ráth György U. 7-9, Budapest, 1122, Hungary.ORCID http://orcid.org/0000-0003-2054-8447
László TordayDepartment of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, 6720, Hungary.ORCID http://orcid.org/0000-0002-2911-5499
Anita SejbenDepartment of Pathology, University of Szeged, Állomás U. 1, Szeged, 6725, Hungary. sejben.anita@gmail.com.ORCID http://orcid.org/0000-0002-9434-2989

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPOLE mutant phenotype in colon adenocarcinomas represents a rare molecular subtype. These tumours are generally responsive to immune-checkpoint inhibition therapy and, therefore, are currently considered as a subtype with good prognosis. We hereby present the first detailed case presentation of a POLE mutant colon adenocarcinoma with useful microscopic features. CASE REPORT: A 53-year-old male patient's colon adenocarcinoma histologically showed wide variety of growth patterns and massive intra- and peritumoural lymphocytic infiltrate. The majority of the tumour consisted of a high-grade component resembling medullary carcinoma of the colon, while approximately one-third of the tumour was composed of conventional areas exhibiting a tubular pattern. A minority of the tumour was constituted by poorly cohesive rhabdoid cells. Immunohistochemistry was performed, and colorectal origin was proven with CDX-2 and SATB2. Furthermore, proficiency in mismatch repair proteins and SMARCB1 deficiency was observed. The unusually high-grade colon adenocarcinoma, with areas mimicking medullary carcinoma, and generally aggressive morphology raised suspicion of microsatellite instability. The diverse morphology and the SMARCB1 deficiency also raised suspicion of ultramutation caused by POLE alteration. Next-generation sequencing panel confirmed a pathogenetic mutation in POLE exon 9: p.Pro286Arg, c.857C > G. DISCUSSION: The diverse, high-grade morphology and increased intratumoural lymphoid infiltration should raise suspicion for POLE-mutated adenocarcinoma during everyday histopathological practice. Mismatch repair proficiency results on immunohistochemistry should not determine the final diagnosis, as only a minor percentage of these tumours are MSI. In every case suspicious for POLE-mutated adenocarcinoma, a 500-cancer gene panel should be carried out.

Indexed as

AdenocarcinomaColonic NeoplasmsMutationDNA Polymerase IIHumansMaleMicrosatellite InstabilityMiddle AgedPoly-ADP-Ribose Binding ProteinsDNA Polymerase IIPOLE protein, humanPoly-ADP-Ribose Binding ProteinsImmune-checkpoint inhibition therapyNext-generation sequencingPOLE-mutant colon adenocarcinomaPOLE mutation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.